William Sharfman

Associate Professor

1990 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Interleukin-1alpha Medicine & Life Sciences
Safety Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2018

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0

Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L., Gajewski, T. F., Gastman, B., Lawson, D. H., Lutzky, J., McDermott, D. F., Margolin, K. A., Mehnert, J. M., Pavlick, A. C., Richards, J. M., Rubin, K. M., Sharfman, W., Silverstein, S., Slingluff, C. L. & 8 othersSondak, V. K., Tarhini, A. A., Thompson, J. A., Urba, W. J., White, R. L., Whitman, E. D., Hodi, F. S. & Kaufman, H. L., May 30 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 44.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Consensus
Skin
Advisory Committees
Radiosurgery
metastasis
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
lungs

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting

Rowe, S., Luber, B., Makell, M., Brothers, P., Santmyer, J. A., Schollenberger, M. D., Quinn, H., Edelstein, D. L., Jones, F. S., Bleich, K., Sharfman, W. & Lipson, E., Jan 1 2018, (Accepted/In press) In : Molecular oncology.

Research output: Contribution to journalArticle

Melanoma
DNA
Neoplasms
Tumor Burden
Disease Progression

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib

Long, G. V., Eroglu, Z., Infante, J., Patel, S., Daud, A., Johnson, D. B., Gonzalez, R., Kefford, R., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W., McWilliams, R., Sznol, M., Redhu, S., Gasal, E., Mookerjee, B., Weber, J. & Flaherty, K. T., Mar 1 2018, In : Journal of Clinical Oncology. 36, 7, p. 667-673 7 p.

Research output: Contribution to journalArticle

Melanoma
Mitogen-Activated Protein Kinase Kinases
Safety
Disease-Free Survival
trametinib